Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chetan Huded

Interventional Cardiology Kansas City, MO Medical Doctor

NPI 1376839894 CMS profile 431091

5844 Nw Barry Rd Ste 230, Kansas City, MO 64154

Open in the dashboard

General payments

$61,017

253 records reported · program years 2019–2025

Research payments

$2,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$451,623 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Chetan Huded of Kansas City, MO is reported in the CMS Open Payments database as having received $61,017 across 253 general payments and $2,000 in research payments paid to them. Separately, studies naming them as principal investigator received $451,623 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,955 62
2024 General $13,031 76
2023 General $2,585 33
2023 Research $2,000 1
2022 General $2,047 22
2021 General $739 10
2020 General $2,662 21
2019 General $1,995 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chetan Huded
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Chetan Huded were reported at $37,955. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Chetan Huded Interventional Cardiology median Middle half National median
2019 $1,995 $1,097 $329–$3,048 $163
2020 $2,662 $473 $161–$1,480 $114
2021 $739 $677 $233–$1,827 $132
2022 $2,047 $978 $333–$2,724 $149
2023 $2,585 $1,136 $382–$2,986 $160
2024 $13,031 $1,181 $395–$3,326 $164
2025 $37,955 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $39,529 91 payments
  2. Edwards Lifesciences Corporation $11,127 45 payments
  3. Abbott Laboratories $4,482 53 payments
  4. Medtronic, Inc. $2,552 25 payments
  5. Medtronic Vascular, Inc. $2,353 17 payments
  6. Shockwave Medical, Inc $424 4 payments
  7. AstraZeneca Pharmaceuticals LP $159 3 payments
  8. Philips Electronics North America Corporation $150 1 payment
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $32 2 payments
  10. Penumbra, Inc. $30 2 payments
  11. Other $178 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $28,106 10 payments
  2. Food and Beverage $12,554 187 payments
  3. Travel and Lodging $11,174 48 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,063 6 payments
  5. Education $120 2 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN FLX $16,821 30 payments
  2. WATCHMAN Access System $12,131 37 payments
  3. WATCHMAN $9,280 7 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $8,184 21 payments
  5. CoreValve Evolut $2,172 14 payments
  6. EVOQUE $1,768 10 payments
  7. COREVALVE EVOLUT R $1,720 16 payments
  8. Omnilink Elite vascular stent system $1,223 3 payments
  9. RESOLUTE ONYX $832 9 payments
  10. AMPLATZER AMULET $567 9 payments
  11. Other $4,415 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

883

Median for Interventional Cardiology: 2,236

Drug cost

$168,039

Median for Interventional Cardiology: $380,412

Branded share of claims

28.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 99 $93,006
Jardiance Empagliflozin Brand 31 $32,670
Entresto Sacubitril/Valsartan Brand 22 $22,054
Repatha Sureclick Evolocumab Brand 16 $13,409
Metoprolol Succinate Generic 103 $1,674
Rosuvastatin Calcium Generic 35 $666
Atorvastatin Calcium Generic 100 $613
Clopidogrel Clopidogrel Bisulfate Brand 57 $543
Warfarin Sodium Generic 47 $523
Losartan Potassium Generic 55 $408

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$149,644

Medicare's payments for the services billed

Medicare patients

607

Average age 77

Services billed

908

267 women, 340 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Atrial fibrillation 58%
Heart failure 55%
Arthritis 44%
Chronic kidney disease 43%
Diabetes 39%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

254 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record